Quarterly Financial Results for Period Ended June 30, 2026 - Contains consolidated financial statements including balance sheet as of June 30, 2026 and December 31, 2025, income statements for Q2 2026 and six-month period ended June 30, 2026 compared to prior year periods Material Changes and Business Operations - Reports on operational performance, business segment results, and material changes…

Our analysis rates this filing CAUTIOUS. The elevated concern level of 6.8/10 reflects a company in transition executing an aggressive acquisition strategy with material execution risks. The primary concern is not financial distress or existential threat, but rather the substantial integration…

Concern level: HIGH (6.8/10). Key factors: One high-severity risk identified with severity 7/10: Significant acquisition activity and integration risk from three major acquisitions (Penumbra Inc., Nalu Medical, Scivita Medical) completed within H1 2026, representing aggressive M&A velocity and substantial goodwill impairment exposure; Risk trend is INCREASING with overall risk score of 6.8/10,…

Notable risk changes: Three major acquisitions completed in H1 2026 (Penumbra Inc. on 1/15/26, Nalu Medical on 1/27/26, Scivita Medical on 3/31/26) creating substantial integration execution risk and goodwill impairment exposure not present in prior periods; Significant contingent consideration obligations structured with revenue-based payments and R&D/regulatory milestone triggers - creates uncertain future cash…

The model predicts BSX will outperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.